Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046876 in Advanced Solid Tumors
NCT07090499Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Aug 2025
- Primary completion
- Jul 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label trial of PF-08046876 in solid tumor, bladder cancer, non-small cell lung cancer (NSCLC) and 3 more (8 arms), sponsored by Pfizer. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Number of Participants With Dose-limiting Toxicities and 3 more. Started Aug 2025; status: recruiting.
02
Drugs
PF-08046876
03
Conditions
solid tumorbladder cancernon-small cell lung cancer (NSCLC)head and neck cancer (HNC)esophageal cancer
Beyond the preview
Go deeper on NCT07090499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07090499.